MedTrace Logo

Comparison of Anterior Corneal Optical Aberration Induced by CK and Hyperopic LASIK

NCT04676620 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2020-12-21

No results posted yet for this study

Summary

Conductive keratoplasty (CK) had shown to be a safe and effective procedure for the treatment of low to moderate hypeopia. It had been approved by the U.S. Food and Drug Administration (FDA) to treat presbyope in early 2004. CK appeals to both surgeons and patients as it avoids the need for flap creation, the use of high intraocular pressure (IOP), or tissue ablation. It utilizes "blended vision" rather than the true monovision used with laser in situ keratomileusis (LASIK), which patients tolerate more readily. There is very little reported research about the induction of wavefront aberration by CK. The symptomatology of high order aberrations (HOA) and the way individual Zernike functions were correlated with visual acuity, contrast sensitivity, visual symptoms. This study measured the HOA created by surgically induced myopic shift via CK and LASIK in an effort to better understand the phenomena of regression, multifocality, pseudo-accommodation and monovision.

Conditions

  • Refractive Error

Interventions

PROCEDURE

CK surgery

CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.

Sponsors & Collaborators

  • Tianjin Eye Hospital

    collaborator OTHER

  • Wang Hongxia

    lead OTHER

Principal Investigators

  • Hongxia Wang, director · Shanghai Guanghua integrated traditional Chinese and Western Medicine Hospital

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676620 on ClinicalTrials.gov